Oct 2026· JAMA Network Open· Vol 9, pp. e2639517· 0 citations· 16 references
Medicine
TL;DR
It is suggested that treatment-emergent skin toxic effects may serve as an early clinical marker of treatment benefit in patients receiving first-line enfortumab vedotin plus pembrolizumab and warrant prospective validation.
Abstract
Key Points Question Among patients with locally advanced or metastatic urothelial carcinoma receiving first-line enfortumab vedotin plus pembrolizumab, is treatment-emergent skin toxic effects associated with improved clinical outcomes? Findings In this cohort study of 185 patients, treatment-emergent skin toxic effects occurred in more than half of patients (53%) and was associated with longer overall survival in time-dependent analyses accounting for immortal-time bias. Meaning These findings suggest that treatment-emergent skin toxic effects may serve as an early clinical marker of treatment benefit in patients receiving first-line enfortumab vedotin plus pembrolizumab and warrant prospective validation.
Treatment opportunities using the enfortumab vedotin plus pembrolizumab (EV+P) combination are expanding for patients with unresectable or metastatic urothelial carcinoma. We report the case of a 93-year-old man with bladder cancer and lung metastases who received EV+P therapy and achieved a complete response. By omitt...
Kazumasa Jojima, A. Minato, Yuto Tsubonuma et al.· Urologia internationalis· 0 citations
Background Skin toxicity is a common adverse event associated with enfortumab vedotin plus pembrolizumab (EVP) but its association with treatment outcomes remains unclear. We aimed to evaluate this association in patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Patients and methods This prosp...
K. Tamura, T. Tsujino, R. Taoka et al.· ESMO real world data and dig...· 0 citations
Abstract Enfortumab vedotin (EV), pembrolizumab, and EV plus pembrolizumab (EV/P) have rapidly reshaped the treatment landscape of advanced urothelial carcinoma, but toxicity increasingly determines treatment delivery, treatment continuity, and real-world benefit. As EV/P moves into broader clinical use, clinicians mus...
Jabra G. Zarka, D. Childs, Miguel Muniz Rincon et al.· The Oncologist· 0 citations
There is currently no evidence regarding the extent to which bone metastases affect the incidence of side effects during pemetrexed therapy, and patients with lung adenocarcinoma might benefit from a treatment regimen without pemetrexed or from closer monitoring during therapy, in line with a personalized treatment app...
C. Riedel, Christian Neumann, R. Heller et al.· Cancers· 0 citations
Simple Summary Tebentafusp is a novel therapy and the first treatment shown to improve survival in patients with advanced uveal melanoma. Because it directs the immune system against a protein that is also found on normal pigment-producing cells in the skin, skin-related side effects are common, particularly rash and i...
Ioannis-Alexios Koumprentziotis, Aikaterini Bakella, V. Nikolaou et al.· Cancers· 0 citations
Importance
Initial enfortumab vedotin (EV) dose selection is increasingly relevant in advanced urothelial carcinoma (UC). Reduced starting doses may be selected for some patients, but their associations with clinical outcomes and tolerability remain uncertain.
Objective
To evaluate the association of physician-select...
In-Ho Kim, Chang Gon Kim, Jungmin Jo et al.· JAMA Network Open· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
